Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00911625 · ClinicalTrials.gov registry record · Phase 4

Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

A Phase 4 study of Type 2 Diabetes and Renal Insufficiency, sponsored by Loyola University.

Completed
Registry status
Phase 4
Development phase
114
Enrollment target
3
Study locations

NCT00911625: Completed Phase 4 study of Type 2 Diabetes and Renal Insufficiency, sponsored by Loyola University.

NCT00911625 is a Phase 4 study of Type 2 Diabetes and Renal Insufficiency that has completed, run by Loyola University. The registered enrollment target is 114 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00911625, a Phase 4 study of Type 2 Diabetes and Renal Insufficiency, has completed, sponsored by Loyola University.

COMPLETED
Registry status
Phase 4
Development phase
114 participants
Enrollment target
3
Study locations

Study Summary

It is imperative to devise easy to follow, yet appropriate, guidelines for insulin use in renal-impaired patients. This will be done by comparing two regimens: 1) glargine once daily plus mealtime glulisine based on weight alone and 2) a predetermined dosing reduction algorithm with glargine/glulisine based on weight with reduction for decreased estimated GFR by MDRD as follows: \< 30 ml/min/1.73m2 or on dialysis reduce dose by 50% from weight based calculation.

Conditions Studied

Type 2 Diabetes Renal Insufficiency

Interventions

  • DRUG 0.5 units/kg daily insulin
  • DRUG 0.25 units/kg daily insulin

Study Locations (3)

Illinois

  • Northwestern University Medical Center - Chicago
  • Rush University Medical Center - Chicago
  • Loyola University Hospital - Maywood

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 2009-01-21
Est. Completion 2011-06-30
Phase Phase 4

Sponsor

Loyola University

92 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00911625

The ClinicalTrials.gov registry entry for NCT00911625 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (90% lower). The listed sponsor is Loyola University, which has 92 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which 0.5 units/kg daily insulin is the first listed.

NCT00911625 reports 3 study locations spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT00911625 about?

NCT00911625 is a clinical study titled "Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency". It is imperative to devise easy to follow, yet appropriate, guidelines for insulin use in renal-impaired patients. This will be done by comparing two regimens: 1) glargine once daily plus mealtime glulisine based on weight alone and 2) a predetermined dosing reduction algorithm with glargine/glulisi...

What is the current status of trial NCT00911625?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 114 participants. The study started on 2009-01-21. Estimated completion is 2011-06-30.

What conditions does trial NCT00911625 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Renal Insufficiency.

What interventions are being tested in trial NCT00911625?

The interventions under investigation include: 0.5 units/kg daily insulin (DRUG), 0.25 units/kg daily insulin (DRUG).

Who is sponsoring clinical trial NCT00911625?

This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00911625 being conducted?

This trial has 3 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

Renal Insufficiency

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.